Clinical Trials & Medical Discoveries The most recent news and results from scientific and medical research, covering all aspects of healthcare, including testing, diagnosis, and treatment. Stay up-to-date on the latest medical discoveries and breakthroughs with announcements of new products to be tested, upcoming clinical trials and studies, and newly published results. Also included are updates regarding funding decisions, company performance, and legal news.

Latest

Nov 29, 2016, 04:00 ET Pharmalink Announces European Orphan Drug Designation For Nefecon® For Treatment Of Iga Nephropathy, An Inflammatory Kidney Disease

Pharmalink AB, a specialty pharma company, announces that the European Commission (EC) has granted Orphan Medicinal Product (OMP) designation in...


Nov 28, 2016, 18:01 ET Blueprint Medicines Announces Proof-of-Concept Data from Global Phase 1 Clinical Trial of BLU-554 in Patients with Advanced Hepatocellular Carcinoma

Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically...


Nov 28, 2016, 16:45 ET DATATRAK Releases Powerful Clinical Trial Management System

DATATRAK International, Inc. (OTCQX: DTRK), has released their innovative clinical trial management system, CTMS 360°. DATATRAK's CTMS is a robust,...


Nov 28, 2016, 16:05 ET Jazz Pharmaceuticals Announces That Patient Enrollment is Complete for the Phase 3 Study of JZP-110 Evaluating Excessive Sleepiness in Narcolepsy

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that patient enrollment has been completed in its Phase 3 study evaluating JZP-110 in...


Nov 28, 2016, 12:00 ET Worldwide Clinical Trials Webinar to Address Emerging Trends in Clinical Trial Methodology for Orphan Disease Drug Development

Worldwide Clinical Trials (http://www.worldwide.com ) will present a webinar, titled "Necessity is the Mother of Invention: The Impetus for...


Nov 28, 2016, 10:43 ET Micell Technologies Announces First Patient Enrolled In Landmark Registration Trial Of MiStent In Japan

Micell Technologies, Inc. (Micell) announced enrollment of the first patient in DESSOLVE J: a prospective, randomized, balanced, controlled,...


Nov 28, 2016, 10:07 ET ImMAGE Biotherapeutics Announces Positive Results from Animal Studies

ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company, announced today that is has successfully completed animal trials. The...


Nov 28, 2016, 09:41 ET New Data and Analyses on FYCOMPA and BANZEL at American Epilepsy Society Meeting Demonstrate Eisai's Continued Commitment to the Epilepsy Community

Eisai Inc. announced today the presentation of 12 posters during the 70th annual American Epilepsy Society (AES) Annual Meeting, highlighting data...


Nov 28, 2016, 09:05 ET PharmaMar Begins a Phase I Study of PM1183 in Japan for the Treatment of Solid Tumors

PharmaMar (MCE:PHM) has announced the start of an open-label, multicenter, Phase I study in Japan to evaluate the recommended dose (RD) of PM1183...


Nov 28, 2016, 09:00 ET Nature Cell Co., Ltd. Receives U.S. FDA Approval for Phase I and II Alzheimer's Clinical Trial

Nature Cell Co., Ltd. (Nature Cell) (CEO, Dr. Jeongchan Ra), a leading biotechnology company, announces AstroStem's approval for Phase I and Phase...


Nov 28, 2016, 08:30 ET Foamix Announces Completion of Patient Enrollment in Phase 3 Acne Trials for Minocycline Foam FMX101

Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) ("Foamix" or the "Company"), a clinical stage specialty pharmaceutical company focused on developing and...


Nov 28, 2016, 08:08 ET BiondVax Announces Third Quarter 2016 Financial Results and Update

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing a...


Nov 28, 2016, 08:00 ET Case Studies by Charles K. Lee, MD, FACS, Clearly Validates Efficacy and Safety of Medela's NPWT Devices

Medela Healthcare proudly presents the results of a case series which prove the clinical efficacy of Medela's Invia® Liberty™ and...


Nov 28, 2016, 08:00 ET MabVax Therapeutics Enrolls First Patients in Expansion of Phase I Clinical Trial Treating Newly Diagnosed Pancreatic Cancer Patients

MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), a clinical stage immuno-oncology drug development company, reported that the first patients have...


Nov 28, 2016, 08:00 ET Emerald Medical Application's Dermacompare Technology Chosen as One of Four Start Up Technology Winners of Merck's Health Innovation Technology Scouts (HITS) Program

Emerald Medical Applications Corp. (OTCQB: MRLA) ("Emerald" or the "Company"), the Israeli-based company engaged in the development and sale of...


Nov 28, 2016, 07:30 ET Intec Pharma Enters into Agreement with the Michael J. Fox Foundation Around Its Phase III Trial Recruitment

Intec Pharma Ltd. (Nasdaq: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion...


Nov 28, 2016, 07:00 ET Neovasc Receives Regulatory Approval to Initiate TIARA II CE Mark Study

NASDAQ: NVCN TSX: NVC VANCOUVER, Nov. 28, 2016 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVC) today announced...


Nov 28, 2016, 06:03 ET Innovate Biopharmaceuticals, Targeting Celiac Disease And Ulcerative Colitis, To Present At The Piper Jaffray Healthcare Conference In New York On Tuesday, Nov. 29

Innovate Biopharmaceuticals Inc., a clinical stage biotechnology company with two drug candidates entering clinical trials for the treatment of...


Nov 28, 2016, 05:00 ET Head Impacts Lead to Brain Changes in High School Football Players

Brain imaging exams performed on high school football players after just one season revealed changes in both the gray and white matter that...


Nov 28, 2016, 03:05 ET PharmaMar débute une étude de phase I sur le PM1183 au Japon pour le traitement des tumeurs solides

PharmaMar (MCE : PHM) a annoncé le début d'une étude ouverte, multicentrique, de phase I au Japon pour évaluer la dose recommandée (DR) de PM1183...


Nov 28, 2016, 03:05 ET PharmaMar avvia uno studio di fase I sul PM1183 in Giappone per la cura dei tumori solidi

PharmaMar (MCE: PHM) ha annunciato l'avvio di uno studio di fase I in aperto, multicentrico, in Giappone per valutare la dose raccomandata (RD)...


Nov 28, 2016, 03:05 ET PharmaMar beginnt eine Phase I-Studie mit PM1183 in Japan für die Behandlung solider Tumoren

PharmaMar (MCE: PHM) hat den Beginn einer mulitzentrischen Open Label Phase I-Studie in Japan zur Bestimmung der empfohlenen Dosis von PM1183...


Nov 28, 2016, 02:05 ET Santen Announces Phase III SAKURA Program Topline Results in Patients with Non-Infectious Uveitis of the Posterior Segment

Santen Pharmaceutical Co., Ltd. (hereinafter, "Santen"), a specialty ophthalmology company headquartered in Osaka, Japan, today announced the...


Nov 28, 2016, 01:00 ET ARA 290 Obtains European Union Orphan Drug Designation for Prevention of Graft Loss in Pancreatic Islet Transplantation

Araim Pharmaceuticals, a clinical stage drug development company with a unique platform technology for activating post-injury tissue repair and...


Nov 25, 2016, 09:16 ET Janssen soumet une demande à l'AEM afin de solliciter l'agrément de l'anticorps monoclonal anti-interleukine-23 guselkumab pour le traitement du psoriasis en plaques modéré à sévère

Janssen-Cilag International NV (Janssen) a annoncé aujourd'hui la soumission d'une demande d'autorisation de mise sur le marché à l'Agence...


Most Viewed